Advantages of alpha1-adrenoblocker tamsulosin (Omnik® OKAS®) as a first-line drug for prostate adenoma patients treatment


DOI: https://dx.doi.org/10.18565/therapy.2021.1.188-193

Spivak L.G.

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
Abstract. Article deals with the points of treatment methods choice in case of urinary dysfunction symptoms in patients with benign prostatic hyperplasia (BPH), the principles of selection and the optimal timing of pharmacotherapy initiation. Among the drugs for BPH treatment, special attention is paid to the original form of tamsulosin as controlled release tablets, which, along with good characteristics of proven efficacy and tolerance, has exceptional pharmacokinetic features.
Keywords: symptoms of urination disorder, benign prostatic hyperplasia, alpha1-blockers, tamsulosin, Omnik® OKAS®
Read entire article

Literature


  1. Gravas S., Bach T., Drake M. et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO). European Association of Urology 2017. Available at: https://uroweb.org/wp-content/uploads/13-Non-Neurogenic-Male-LUTS_2017_web.pdf (date of access – 01.02.2021).

  2. Martin S.A., Haren M.T., Marshall V.R. et al. Members of the Florey Adelaide Male Ageing Study. Prevalence and factor associated with uncomplicated storage and voiding lower urinary tract symptoms in community dwelling Australian men. World J Urol. 2011; 29(2): 179–84. doi: 10.1007/s00345-010-0605-8.

  3. Abrams P., Cardozo L., Fall M. et al. Standardisation sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002; 21(2): 167–78. doi: 10.1002/nau.10052.

  4. Oelke M., Bachmann A., Descazeaud A. et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology, Update February 2012. Available at: www.uroweb.org/gls/pdf/12_Male_LUTS_LR.pdf (date of access – 01.02.2021).

  5. Coyne K.S., Gilsenan A.W., Midkiff. K.D. et al. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007; 61(9): 1437–45. doi: 10.1111/j.1742-1241.2007.01508.x.

  6. Emberton M., Cornel E.B., Bassi P.F. et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008; 62(7): 1076–86. doi: 10.1111/j.1742-1241.2008.01785.x.

  7. Аляев Ю.Г., Винаров А.З., Демидко Ю.Л., Спивак Л.Г. Лечение хронического простатита как профилактика возможного развития аденомы предстательной железы. Урология. 2012; 2: 39–43. [Alyaev Yu.G., Vinarov A.Z., Demidko Yu.L., Spivak L.G. Treatment of chronic prostatitis in prophylaxis of prostatic adenoma. Urologiya = Urology. 2012; 2: 39–43 (In Russ.)].

  8. Голубцова Е.Н., Богданов А.Б., Велиев Е.И. Комбинированная терапия симптомов нижних мочевых путей у мужчин: современное состояние проблемы. Эффективная фармакотерапия. 2015; 26: 14–21. [Golubtsova Ye.N., Bogdanov A.B., Veliyev Ye.I. A Combination th erapy of the lower urinary tract symptoms in men: Updated status. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2015; 26: 14–21 (In Russ.)].

  9. Ball A.J., Feneley R.C., Abrams P.H. The natural history of untreated «prostatism». Br J Urol. 1981; 53(6): 613–16. doi: 10.1111/j.1464-410x.1981.tb03273.x.

  10. Богданов А.Б., Лукьянов И.В., Велиев Е.И. Эффективность и безопасность комбинированного применения доксазозина и финастерида при лечении доброкачественной гиперплазии предстательной железы. Трудный пациент. 2007; 3: 41–45. [Bogdanov A.B., Lukianov I.V., Veliev E.I. Efficiency and safety of combined use of doxazosin and finasteride in the treatment of benign prostatic hyperplasia. Trudniy patsient = Difficult patient. 2007; 3: 41–45 (In Russ.)].

  11. Корнеев И.А., Алексеева Т.А., Коган М.И., Пушкарь Д.Ю. Эпидемиология расстройств мочеиспускания у мужчин Российской Федерации. Урология. 2016; 2-S2: 70–75. [Korneev I.A., Alekseeva T.A., Kogan M.I., Pushkar D.Yu. Epidemiology of urinary disorders in men in the Russian Federation. Urologiya = Urology. 2016; 2-S2: 70–75 (In Russ.)].

  12. Djavan B., Fong Y.K., Harik M. et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64(6): 1144–48. doi: 10.1016/j.urology.2004.08.049.

  13. Ефремов Е.А., Мельник Я.И., Охоботов Д.А. Современные аспекты лечения ДГПЖ у сексуально активных пациентов. Эффективная фармакотерапия. 2008; 20: 18–23. [Efremov E.A., Melnik Ya.I., Okhobotov D.A. Aspects of current treatment of benign prostatic hyperplasia in sexually active. Effektivnaya farmakoterapiya = Effective pharmacotherapy. 2008; 20: 18–23 (In Russ.)].

  14. Farmer R., Hutchison A., Chapple R. Comparison of the treatment regimes of new and existing LUTS/BPH patients in 6 European countries. Eur Urol Suppl. 2004; 3: 60 (abs. 230).

  15. Урология. Российские клинические рекомендации. Под. ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа. 2016; 496 с. [Urology. Russian clinical guidelines. Ed. by Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Moscow: GEOTAR-Media. 2016; 416 pp. (In Russ.)]. ISBN 978-5-9704-3649-3.

  16. Спивак Л.Г., Винаров А.З., Евдокимов М.С. Медикаментозная терапия больных аденомой предстательной железы с расстройствами мочеиспускания. Урология. 2012; 6: 96–99. [Spivak L.G., Vinarov A.Z., Evdokimov M.S. Drug therapy in patients with adenoma of the prostate gland with urination disorders. Urologiya = Urology. 2012; 6: 96–99 (In Russ.)].

  17. Лоран О.Б., Серегин А.А. Эффективность и безопасность применения препарата Омник Окас для пациентов с симптомами нижних мочевыводящих путей на фоне доброкачественной гиперплазии простаты в рутинной клинической практике в Российской Федерации. Урология. 2018; 2: 68–74. [Loran O.B., Seregin A.A. The effectiveness and safety of Omnik Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia in the routine clinical practice in the Russian Federation (prospective multi-center observing program). Urologiya = Urology. 2018; 2: 68–74 (In Russ.)]. doi: https://dx.doi.org/10.18565/urology.2018.2.68-74.

  18. Djavan B., Chapple C., Milani S., Marberger M. State of art on the efficacy and tolerability of alpha1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of BPH. Urology 2004; 64(6): 1080–81. doi: 10.1016/j.urology.2004.07.031.

  19. American Urological Association Guidelines. Management of Bening Prostatic Hyperplasia (BPH). 2010. Available at: https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014) (date of access – 01.02.2021).


About the Autors

Leonid G. Spivak, MD, professor of the Institute of urology and human reproductive health of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), chairman of the board of the Association of Specialists in Conservative Therapy in Urology «ASPECT». Address: 119435, Moscow, 2/1 Bolshaya Pirogovskaya Str. E-mail: leonid.spivak@gmail.com

Back to Content

Бионика Медиа